Volume 8 Supplement 1

5th European Workshop on Immune-Mediated Inflammatory Diseases

Open Access

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus

  • R Martínez-Pérez1,
  • A Fernández-Nebro2,
  • M López-Lasanta2,
  • M L Velloso-Feijoo1,
  • A Muñoz-Jiménez1,
  • J López Longo3 and
  • J L Marenco1
Journal of Translational Medicine20108(Suppl 1):P70

https://doi.org/10.1186/1479-5876-8-S1-P70

Published: 25 November 2010

Introduction

Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease of unknown etiology. The evolution of the disease is unpredictable. Most patients follow a chronic course and have flare-ups or exacerbations, with a number of hospital admissions.

Hypothesis and objectives

The use of Rituximab (RTX) decrease the hospital admissions in SLE patients refractory to immunosuppressive therapy.

Material and methods

This is an observational, retrospective and multicenter study. Sequential observation was made at baseline, at 24th week and final visit. The outcome variables were: clinic improvement measured by SLEDAI, Physician’s Global Assessment (PGA) and patient hospitalization for SLE during the 24th week and final visit. Statistical analysis of the qualitative and quantitative variables was done by Chi-square and T-test/Wolcoxon, respectively.

Results

We treated 46 patients (94% women), mean age 36.50 ± 11.47 ages, 91% Caucasians.

Monitoring: mean of 21,1±13,9 months. The main reason for use of RTX was: nephritis (24%,) arthritis (28%), thrombocytopenia (11%), neurological (13%), cutaneous (13%) and others (11%).

The most common dose used was 2x1g (87%). The median of cycles was 2 (rank 1-3). Patients treated with RTX improved SLEDAI, PGA and reduced hospital admissions (table 1).
Table 1

Endpoints.

 

Baseline

24th week

Final Visit

SLEDAI (0–105), median (rank)

14.5 (7.8-22.3)

4.0 (2.0–6.0)**

2.0 (0.0–4.0)**

PGA (0–3), median (rank)

2.8 (2.0–3.0)

0.0 (0.0–1.0)**

0.0 (0.0-1.0)

Hospitalization, n (%)

25 (54%)

1 (2.3%)**

2 (4%)**

**p <0,0005 respect to baseline.

Conclusions

RTX may be effective in SLE patients refractory to immunosuppressive therapy, as it gets to control disease activity and reduces hospital admissions. For these reasons, RTX should be considered a therapeutic option of first choice in these patients.

Authors’ Affiliations

(1)
Rheumatology Unit, Valme University Hospital
(2)
Rheumatology Unit, Malaga Civil Hospital
(3)
Rheumatology Unit, Gregorio Marañón University Hospital

Copyright

© Martínez-Pérez et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement